How do oral Wegovy and Foundayo differ?

There is no study comparing them directly. In its own trial (OASIS 4), oral Wegovy produced up to 16.6% weight loss (13.6% among all participants). In its own trial (ATTAIN-1), Foundayo produced up to 12.4% weight loss. Foundayo has no food or water timing restrictions; oral Wegovy requires a 30-minute fast before eating. Both start at $149/month at the lowest dose, rising to $299/month for oral Wegovy and $349/month for Foundayo at the top doses. The right choice depends on your priorities — talk to your doctor.

Are the pills as effective as the injections?

In its own trial (OASIS 4), the semaglutide pill produced up to 16.6% weight loss (13.6% among all participants); the semaglutide injection produced 14.9% in its own trial (STEP 1) — separate trials, not a head-to-head comparison. In its own trial (ATTAIN-1), orforglipron (Foundayo) produced 12.4% weight loss; tirzepatide (Zepbound) produced 20.9% in its own trial (SURMOUNT-1) — again, separate trials. Foundayo is the first non-peptide (small molecule) oral GLP-1 approved for weight loss.

Can I switch from injection to pill?

For semaglutide, switching from injection to oral is possible — talk to your doctor about the transition. The ATTAIN-MAINTAIN trial showed that people switching from injectable GLP-1 to orforglipron maintained their weight loss. Your doctor needs to manage the switch to get the dose transition right.

Will my insurance cover these new pills?

Coverage is expanding but varies by plan. Commercial insurance plans are increasingly covering oral GLP-1s. For Foundayo, Medicare Part D coverage is expected from July 2026 at about $50/month. Check with your specific plan and ask about manufacturer savings cards.

What about the pipeline — what is coming next?

Retatrutide (triple agonist) showed 28.7% weight loss in Phase 3 — FDA approval estimated for 2027. CagriSema (GLP-1 + amylin) has filed for FDA approval with a decision expected in 2026. Amycretin and MariTide are also in late-stage trials.

Should I wait for something better?

That depends on your situation. The drugs available today produce meaningful weight loss backed by large studies. Pipeline drugs may produce more weight loss, but they are not approved yet and timelines can shift. If you need treatment now, today's options are well-proven.

New Weight Loss Drugs & Pills in 2026

Two new pills.

Oral Wegovy (semaglutide, approved Dec 2025) — about 15–17% weight loss, $149–$299/month. Foundayo (orforglipron, approved April 2026) — about 12.4% weight loss, $149–$349/month, no food restrictions. Both are daily pills, dramatically cheaper than injectable GLP-1s.

Oral Wegovy — the semaglutide pill

Approved December 2025Strong

Semaglutide — the same drug in Wegovy and Ozempic — is now available as a daily pill. This is a significant development because it removes the need for weekly injections and costs $149–$299/mo by dose, compared to $349–$399/mo self-pay for the injection ($1,349/month at list price).

Key facts

Generic name

Semaglutide (oral)

Brand name

Wegovy (pill)

Dose

25mg daily (after titration)

Weight loss

Up to 16.6% (OASIS 4)

List price

$149–$299/month self-pay

With insurance

~$25/month (commercial)

Manufacturer

Novo Nordisk

How to take

Empty stomach, small sip of water, wait 30 min

What makes it significant

Before this approval, semaglutide for weight loss was only available as a weekly injection. Self-pay for the injection is $349–$399/mo via NovoCare Pharmacy (list price $1,349/month); the pill is priced separately, from $149/month. In its own trial (OASIS 4), the pill produced up to 16.6% weight loss (13.6% among all participants); the injection produced 14.9% in its own trial (STEP 1) — separate trials, not a head-to-head comparison.

The trade-off

The pill must be taken on an empty stomach with no more than 120ml of plain water, and you need to wait at least 30 minutes before eating, drinking, or taking other medications. For some people, this daily routine is easy. For others, it is inconvenient enough to prefer injection or a different pill.

Full semaglutide overview (injection + pill) →

Foundayo — the first no-restrictions GLP-1 pill

Approved April 2026Strong

Foundayo (orforglipron) is a fundamentally different kind of GLP-1 drug. Unlike semaglutide and tirzepatide, which are large protein molecules, orforglipron is a small molecule — meaning it absorbs through the gut without any food or water timing restrictions. You can take it any time of day, with or without food.

Key facts

Generic name

Orforglipron

Brand name

Foundayo

Dose

Up to 17.2mg daily (titrated)

Weight loss

About 12.4% (ATTAIN-1)

List price

$149-$349/month

With insurance

~$25/month (commercial)

Manufacturer

Eli Lilly

How to take

Any time, with or without food

What makes it significant

Foundayo is the first non-peptide (small molecule) GLP-1 approved for weight loss. This matters because it can be taken without any food or water timing restrictions — unlike oral Wegovy, which requires a 30-minute fast. It also does not need refrigeration and is priced to be affordable without insurance.

The trade-off

In its own trial (ATTAIN-1), Foundayo produced up to 12.4% weight loss. In their own separate trials, injectable semaglutide produced 14.9% (STEP 1), tirzepatide produced 20.9% (SURMOUNT-1), and oral Wegovy produced up to 16.6% (OASIS 4) — none of these are head-to-head comparisons. For some people, Foundayo's convenience of no food restrictions is the priority; for others, the trial result is.

Medicare coverage

Foundayo is expected to be available under Medicare Part D from July 2026 at about $50/month. This would make it one of the first GLP-1 weight loss medications accessible to Medicare beneficiaries at an affordable price.

Full Foundayo overview →

How they compare

A quick side-by-side of the two new approvals. For a detailed comparison, see the full comparison page.

Oral Wegovy

Weight loss~15-17%

Cost$149-$299/month

Food rules30-min fast required

Dose frequencyOnce daily

Heart benefitProven (SELECT trial)

Available sinceDecember 2025

Foundayo

Weight loss~12.4%

Cost$149-$349/month

Food rulesNone

Dose frequencyOnce daily

Heart benefitNot yet tested

Available sinceApril 2026

The arrival of these two pills means GLP-1 weight loss treatment is now available from about $149/month self-pay. Injectable semaglutide's list price is $1,349/month, though manufacturer self-pay programmes and insurance can bring that down for many people.

What is still in the pipeline

The next wave of weight loss drugs is in late-stage studies. These are not yet approved, and timelines are estimated — but the data is worth knowing about.

Retatrutide (Eli Lilly)

In trials

Triple agonist (GLP-1 + GIP + glucagon)

Trial data

About 28.7% weight loss in Phase 3 (TRIUMPH-4)

Timeline

FDA approval estimated 2027

CagriSema (Novo Nordisk)

In trials

GLP-1 + amylin combination

Trial data

About 20.4% weight loss in Phase 3 (REDEFINE 1)

Timeline

NDA filed December 2025. FDA decision expected 2026.

Amycretin (Novo Nordisk)

In trials

GLP-1 + amylin (single molecule)

Trial data

Up to 22% weight loss in early trials. Phase 3 planned 2026.

Timeline

Earliest approval 2028+

MariTide (Amgen)

In trials

GIP antagonist + GLP-1 agonist (antibody-based)

Trial data

Up to 20% weight loss in Phase 2. Monthly dosing.

Timeline

Phase 3 ongoing. Earliest approval 2027+

Pipeline timelines are estimates and can shift. These drugs are not yet approved, and trial data may change as more results come in. If you need treatment now, today's approved options are well-proven.

Common questions

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Was this page helpful?

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. Prices shown are United States self-pay or list prices and vary by insurance and country.

Next step most people take

Oral Wegovy vs FoundayoDetailed comparison of the two new pills Future treatmentsEverything in the pipeline — retatrutide, CagriSema, and more Can I afford medication?Cost breakdown, savings cards, and patient assistance